Company Description
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States.
It operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX945, an IDR technology that is in Phase 2a study to treat aphthous ulcers in Behçet’s disease; and SGX302, an IDR technology, which is in Phase 2a study for the treatment of mild-to-moderate psoriasis.
Its Public Health Solutions segment engages in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a, 1b, and 1c clinical trials; SGX943, a therapeutic candidate in preclinical studies for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; CiVax, a vaccine candidate for the prevention of COVID-19; and vaccine programs that target filoviruses, such as Marburg and Ebola.
The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in September 2009.
Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
| Country | United States |
| Founded | 1987 |
| IPO Date | Jun 15, 1987 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
| CEO | Christopher Schaber |
Contact Details
Address: 29 Emmons Drive, Suite B-10 Princeton, New Jersey 08540 United States | |
| Phone | 609 538 8200 |
| Website | soligenix.com |
Stock Details
| Ticker Symbol | SNGX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000812796 |
| CUSIP Number | 834223604 |
| ISIN Number | US8342236044 |
| Employer ID | 41-1505029 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Christopher J. Schaber Ph.D. | Chairman of the Board of Directors, Chief Executive Officer and President |
| Dr. Oreola Donini Ph.D. | Senior Vice President and Chief Scientific Officer |
| Dr. Richard C. Straube M.D., MSc. | Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 1, 2025 | SCHEDULE 13G | Filing |
| Sep 29, 2025 | 8-K | Current Report |
| Sep 26, 2025 | 424B4 | Prospectus |
| Sep 25, 2025 | EFFECT | Notice of Effectiveness |
| Sep 19, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Aug 27, 2025 | DRS | [Cover] Draft Registration Statement |
| Aug 18, 2025 | 8-K | Current Report |
| Aug 15, 2025 | 424B3 | Prospectus |
| Aug 15, 2025 | 8-K | Current Report |
| Aug 15, 2025 | 424B3 | Prospectus |